The cluster is proportional to market cap (0.22%) and CMO sales aligned with derivative exercise are typical liquidity-driven events, not a strong bearish signal. Watch for any upcoming IMNM news (clinical data, financing) that might have motivated the accelerated selling by the Director.
IMNM drugs
IMNM drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jul 8 $24.01entry
- T+1 · 4mo ago +0.67%α −0.18% · $24.17
- T+5 · 4mo ago −5.91%α −6.78% · $22.59
- T+20 · 3mo ago +6.29%α +3.02% · $25.52
- T+60 · 7w ago −12.99%α −15.49% · $20.89
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Two insiders at Immunome, Director Barchas and CMO Lechleider, collectively sold ~$6.0M of stock over the past week, with the largest executive sale occurring just after derivative exercises. At a $2.7B market cap, these sales represent ~0.22% of market cap, a modest but notable cluster.
Key Financial Metrics
Key Facts
- Director Isaac Barchas sold ~$4.7M total across three trades at $21.95–$24.20 per share (2026-07-02 through 2026-07-07).
- CMO Robert Lechleider exercised 55,000 derivative shares at $0 cost (tax-free) and immediately sold ~55,000 shares for ~$1.24M in open-market trades at $21.95–$23.44 per share (2026-07-02).
- Total cluster open-market sales: ~$5.9M (~0.22% of $2.7B market cap).
- Prior 30d insider activity shows 8 sells totaling $8.0M, the recent cluster extends an ongoing selling pattern.
Financial Impact
~$5.9M in open-market sales, ~0.22% of $2.7B market cap, modest inside selling.
Risk Factors
- Insider selling may increase if a material adverse event is pending.
- Director Barchas' $4.7M sell is the largest single-insider cash-out and may signal reduced conviction at current levels.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-IMNM-1783465406249 |
Track record
20 reports on IMNM
3 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +26.53% at T+60 after the May 28, 2026 report. 6 of 8 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 3/10 Entry $18.39 Now $17.61 −4.24% settles Feb 12
- Nov 9, 20267d ago S-3ASR Neutral 3/10 Entry $18.65 Now $17.61 −5.58% settles Feb 8
- Nov 9, 20267d ago S-3ASR Neutral 3/10 Entry $18.65 Now $17.61 −5.58% settles Feb 8
- Nov 9, 20267d ago 8-K Bearish 5/10 Entry $18.65 Now $17.61 +5.58% settles Feb 8
- Oct 30, 202617d ago SC 13G Neutral 3/10 Entry $18.21 Now $17.61 −3.29% settles Jan 28
- Oct 16, 20264w ago ANALYST-UPGRADE Bullish 4/10 Entry $16.47 Now $17.61 +6.92% settles Jan 13
- Oct 5, 20266w ago 8-K Bullish 6/10 Entry $21.17 Now $17.61 −16.82% settles Dec 30
- Oct 1, 20266w ago ANALYST-UPGRADE Bearish 4/10 Entry $20.89 Now $17.61 +15.70% settles Dec 28
- Sep 21, 20268w ago ANALYST-UPGRADE Bullish 4/10 Entry $25.07 Now $17.61 −29.76% settles Dec 15
- Aug 12, 202613w ago Insider Cluster Neutral 4/10 Entry $26.42 to $18.71 Now $17.61 −33.35% ▼ −29.18% −23.71% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers